$GERN
Geron Corp

2023 Q3 Form 10-Q Financial Statement

#000095017023037931 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $164.0K $29.00K
YoY Change -44.78% -60.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.35M $16.49M
YoY Change 17.31% 121.55%
% of Gross Profit
Research & Development $29.43M $35.49M
YoY Change 19.6% 72.23%
% of Gross Profit
Depreciation & Amortization $110.0K $121.0K
YoY Change 39.24% 68.06%
% of Gross Profit
Operating Expenses $47.78M $51.98M
YoY Change 18.71% 85.32%
Operating Profit -$47.61M -$51.95M
YoY Change 19.18% 85.7%
Interest Expense $2.066M $2.003M
YoY Change 13.7% 26.69%
% of Operating Profit
Other Income/Expense, Net -$92.00K -$11.00K
YoY Change -33.33% -100.99%
Pretax Income -$44.81M -$49.23M
YoY Change 9.16% 75.08%
Income Tax
% Of Pretax Income
Net Earnings -$44.81M -$49.23M
YoY Change 9.14% 75.08%
Net Earnings / Revenue -27320.12% -169748.28%
Basic Earnings Per Share -$0.08 -$0.09
Diluted Earnings Per Share -$0.08 -$0.09
COMMON SHARES
Basic Shares Outstanding 523.4M 508.8M
Diluted Shares Outstanding 579.5M 547.3M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $313.5M $371.4M
YoY Change 60.96% 69.36%
Cash & Equivalents $30.71M $56.90M
Short-Term Investments $282.8M $314.5M
Other Short-Term Assets $6.800M $4.714M
YoY Change 34.39% 22.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $335.1M $377.3M
YoY Change 50.89% 65.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.231M $1.147M
YoY Change 67.94% 78.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.80M $28.28M
YoY Change
Other Assets $5.200M $4.748M
YoY Change -5.57% -16.75%
Total Long-Term Assets $77.93M $38.02M
YoY Change 639.67% 252.47%
TOTAL ASSETS
Total Short-Term Assets $335.1M $377.3M
Total Long-Term Assets $77.93M $38.02M
Total Assets $413.0M $415.3M
YoY Change 77.56% 74.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.68M $7.673M
YoY Change 67.22% 69.72%
Accrued Expenses $41.86M $45.04M
YoY Change -21.18% 46.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $22.06M $10.84M
YoY Change 70.23% 110.03%
Total Short-Term Liabilities $89.39M $72.57M
YoY Change 7.94% 54.8%
LONG-TERM LIABILITIES
Long-Term Debt $29.84M $40.80M
YoY Change -21.06% -9.85%
Other Long-Term Liabilities $3.200M $3.498M
YoY Change -16.36% -12.04%
Total Long-Term Liabilities $29.84M $40.80M
YoY Change -21.06% -9.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $89.39M $72.57M
Total Long-Term Liabilities $29.84M $40.80M
Total Liabilities $119.2M $113.4M
YoY Change -1.15% 23.05%
SHAREHOLDERS EQUITY
Retained Earnings -$1.546B -$1.501B
YoY Change 12.75% 12.86%
Common Stock $1.837B $1.800B
YoY Change 24.16% 22.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $290.6M $298.4M
YoY Change
Total Liabilities & Shareholders Equity $413.0M $415.3M
YoY Change 77.56% 74.38%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$44.81M -$49.23M
YoY Change 9.14% 75.08%
Depreciation, Depletion And Amortization $110.0K $121.0K
YoY Change 39.24% 68.06%
Cash From Operating Activities -$50.84M -$29.60M
YoY Change 71.86% 3.35%
INVESTING ACTIVITIES
Capital Expenditures $200.0K $202.0K
YoY Change -216.96% -388.57%
Acquisitions
YoY Change
Other Investing Activities -$4.530M -$44.24M
YoY Change -145.24% -1636.18%
Cash From Investing Activities -$4.710M -$44.44M
YoY Change -147.86% -1681.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.35M 18.34M
YoY Change 514.27% -74.01%
NET CHANGE
Cash From Operating Activities -50.84M -29.60M
Cash From Investing Activities -4.710M -44.44M
Cash From Financing Activities 29.35M 18.34M
Net Change In Cash -26.20M -55.71M
YoY Change 75.11% -224.53%
FREE CASH FLOW
Cash From Operating Activities -$50.84M -$29.60M
Capital Expenditures $200.0K $202.0K
Free Cash Flow -$51.04M -$29.80M
YoY Change 73.54% 4.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000886744
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-20859
dei Entity Registrant Name
EntityRegistrantName
GERON CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-2287752
dei Entity Address Address Line1
EntityAddressAddressLine1
919 EAST HILLSDALE BOULEVARD
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 250
dei Entity Address City Or Town
EntityAddressCityOrTown
FOSTER CITY
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
473-7700
dei Trading Symbol
TradingSymbol
GERN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
523370675
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56903000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56845000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
535000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
364000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
314475000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
115901000
CY2023Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1187000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
3144000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4179000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3992000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
377279000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
180246000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
28281000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
793000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3841000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4147000
CY2023Q2 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4748000
CY2022Q4 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
5389000
CY2023Q2 us-gaap Assets
Assets
415296000
CY2022Q4 us-gaap Assets
Assets
190575000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7673000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10190000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8232000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11534000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
786000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
925000
CY2023Q2 us-gaap Debt Current
DebtCurrent
10842000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1581000
CY2022Q4 us-gaap Debt Current
DebtCurrent
20945000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45036000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33100000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
72569000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
76694000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3498000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3671000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40802000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30212000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
522000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
390000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1799841000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1493469000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500991000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1413642000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-945000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
298427000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79998000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
415296000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
190575000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35490000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20606000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
62709000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42705000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16490000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7443000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29384000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14142000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
51980000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28049000
us-gaap Operating Expenses
OperatingExpenses
92093000
us-gaap Operating Expenses
OperatingExpenses
56847000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-51951000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27976000
us-gaap Operating Income Loss
OperatingIncomeLoss
-92043000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56651000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4738000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
330000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8591000
us-gaap Investment Income Interest
InvestmentIncomeInterest
442000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2003000
us-gaap Interest Expense
InterestExpense
3925000
us-gaap Interest Expense
InterestExpense
3060000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1110000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1054000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-49227000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28117000
us-gaap Net Income Loss
NetIncomeLoss
-87349000
us-gaap Net Income Loss
NetIncomeLoss
-58215000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
547280946
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
547280946
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
403868713
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
403868713
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
553772809
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
553772809
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
368166148
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
368166148
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-49227000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28117000
us-gaap Net Income Loss
NetIncomeLoss
-87349000
us-gaap Net Income Loss
NetIncomeLoss
-58215000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-786000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-82000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-711000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-621000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50012000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28188000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88075000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58824000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79998000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38122000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
75000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16000
CY2023Q1 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
213337000
CY2023Q1 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
59835000
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
112000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7875000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2961000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
326055000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-49227000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-786000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2023Q2 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
17767000
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
99000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
573000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3945000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
298427000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
126416000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-30098000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-539000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1692000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
97487000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28117000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-82000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2022Q2 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
69916000
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
761000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2058000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
142047000
us-gaap Profit Loss
ProfitLoss
-87349000
us-gaap Profit Loss
ProfitLoss
-58215000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
220000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
129000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4963000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-304000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
487000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
704000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
211000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
28000
us-gaap Share Based Compensation
ShareBasedCompensation
6906000
us-gaap Share Based Compensation
ShareBasedCompensation
3750000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
306000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
285000
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-2411000
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
5507000
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
5805000
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-4094000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75966000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62616000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
355718000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
57049000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
133115000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
90406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-223177000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33237000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8448000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
761000
gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
213337000
gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
69916000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
77602000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
114000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
299387000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70563000
gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-15000
gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
229000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41186000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57209000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35235000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57438000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76421000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior Period Reclassification</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The prior period presentations of other comprehensive loss in the condensed consolidated statements of stockholders' equity and accrued liabilities have been updated to conform to current period presentation. See Note 3 on Accrued Liabilities.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, operating leases, right-of-use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2058000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6906000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3750000
CY2023Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P4Y
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3945000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
34417000
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
34417000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
535000
CY2023Q2 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
535000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
343708000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
980000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
342756000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
39771000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39771000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
364000
CY2022Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
364000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
116142000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
247000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115901000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
284997000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
980000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
284997000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
980000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
75721000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
165000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
28435000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
82000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
104156000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
247000
CY2023Q2 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
22776000
CY2022Q4 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
17040000
CY2023Q2 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
11798000
CY2022Q4 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
5321000
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
7000000
CY2022Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
8350000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
857000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1318000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
584000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
561000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2021000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
510000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45036000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33100000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3558000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
39277000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20031000
CY2023Q2 gern Long Term Debt Gross
LongTermDebtGross
62866000
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
9592000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
483000
CY2023Q2 gern Debt Instrument Unaccrued End Of Term Charge
DebtInstrumentUnaccruedEndOfTermCharge
1147000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
10842000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40802000
gern Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period
LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod
P12M
gern Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity
LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity
P30D
gern Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment
LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment
P12M

Files In Submission

Name View Source Status
0000950170-23-037931-index-headers.html Edgar Link pending
0000950170-23-037931-index.html Edgar Link pending
0000950170-23-037931.txt Edgar Link pending
0000950170-23-037931-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gern-20230630.htm Edgar Link pending
gern-20230630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gern-20230630_cal.xml Edgar Link unprocessable
gern-20230630_def.xml Edgar Link unprocessable
gern-20230630_lab.xml Edgar Link unprocessable
gern-20230630_htm.xml Edgar Link completed
gern-ex10_2.htm Edgar Link pending
gern-ex31_1.htm Edgar Link pending
gern-ex31_2.htm Edgar Link pending
gern-ex32_1.htm Edgar Link pending
gern-ex32_2.htm Edgar Link pending
img43586869_0.jpg Edgar Link pending
img43586869_1.jpg Edgar Link pending
img43586869_2.jpg Edgar Link pending
img43586869_3.jpg Edgar Link pending
img43586869_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gern-20230630_pre.xml Edgar Link unprocessable